05.09.2021 08:44:49
|
Moderna Seeks Conditional Marketing Approval From EMA For COVID-19 Vaccine Booster Shots
(RTTNews) - Moderna Inc. (MRNA) said it submitted for a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level.
The Phase 2 study of mRNA-1273 was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6 months following their second dose.
Moderna noted that an additional analysis showed that a booster dose of mRNA-1273 at the 50 µg dose level induced robust antibody responses and significantly increased geometric mean titers for all variants of concern including Beta (B.1.351) by 32- fold, Gamma (P.1) by 43.6-fold and Delta (B.1.617.2) by 42.3-fold.
On Wednesday, Moderna announced it submitted documents asking approval from the U.S. Food and Drug Administration to allow the use of a third booster dose of its COVID-19 vaccine.
On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has received emergency or other conditional, interim or provisional authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing from the World Health Organization (WHO).
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Moderna Incmehr Nachrichten
20.12.24 |
Freitagshandel in New York: NASDAQ 100 zum Start des Freitagshandels schwächer (finanzen.at) | |
19.12.24 |
Donnerstagshandel in New York: NASDAQ 100 zum Ende des Donnerstagshandels in der Verlustzone (finanzen.at) | |
19.12.24 |
S&P 500-Titel Moderna-Aktie: So viel hätten Anleger an einem Moderna-Investment von vor einem Jahr verloren (finanzen.at) | |
19.12.24 |
Starker Wochentag in New York: NASDAQ 100-Börsianer greifen zum Handelsstart zu (finanzen.at) | |
18.12.24 |
Pluszeichen in New York: S&P 500 startet in der Gewinnzone (finanzen.at) | |
18.12.24 |
Schwacher Wochentag in New York: NASDAQ 100 liegt zum Start im Minus (finanzen.at) | |
16.12.24 |
Börse New York: S&P 500-Börsianer greifen zum Start des Montagshandels zu (finanzen.at) | |
16.12.24 |
Börse New York: Zum Start des Montagshandels Gewinne im NASDAQ 100 (finanzen.at) |
Analysen zu Moderna Incmehr Analysen
19.11.24 | Moderna Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
13.09.24 | Moderna Underweight | JP Morgan Chase & Co. | |
05.08.24 | Moderna Sector Perform | RBC Capital Markets | |
12.01.24 | Moderna Outperform | RBC Capital Markets | |
03.11.23 | Moderna Buy | Goldman Sachs Group Inc. |